CRISPR Therapeutics AG
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
225 / 1361
Position in country
202 / 449
Return on Assets, %
-7
-40.3
Net income margin, %
44.4
-180
EBITDA margin, %
37
-168.2
Debt to Equity, %
0
3.2
Intangible assets and goodwill, %
0
0.2
Revenue CAGR 3Y, %
702.2
12.5
Total Equity change 1Y, %
0.3
-9
Revenue Y, % chg
30885.4
0
P/BV
2.5
1.8
P/S
13.8
10.3
EV/S
9.3
7.5
EV/EBITDA
-16.2
-1.6
Average Analyst recommendation
Hold
Hold
Average upside forecasts, %
36.8
131.1
Expected dividend per share
0
0
Competitors
Ranks
-
MoonLake Immunotherapeutics
00%
-
Vertex Pharmaceuticals Inc
00%
-
CSL Ltd
00%
-
Regeneron Pharmaceuticals Inc
00%
-
Gilead Sciences Inc
00%
-
CRISPR Therapeutics AG
00%
-
Seagen Inc
00%
-
Amgen Inc
00%
-
Moderna Inc
00%
-
AbbVie Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
Switzerland
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
5149.8
Ticker
CRSP.O
ISIN
CH0334081137
IPO date
2016-10-19
Availability on Russian exchanges
Yes
Reporting for
2024-02-21
Date fact. publication of reports
2023-12-31
Company Description
CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: